Medicamen Biotech Ltd

Medicamen Biotech Limited informed the BSE Limited and National Stock Exchange of India Limited that its Register of Members and Share Transfer Books will be closed from September 20, 2026, to September 26, 2026, for the 33rd Annual General Meeting and to determine entitlement for the final dividend for the financial year ended March 31, 2026, with a record date of September 19, 2026.

Medicamen Biotech Ltd share price ticked higher by 2.53% to Rs 242.75. The Company's net profit tanked by 58.43% to Rs 1.85 crore, while revenue from operations plunged by 21.02% to Rs 47.9 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 25.19 lakh crore, rising 4.63%. It has marginally improved by 0.66% over last one week and climbed by 11.20% in last one month while the market capitalization of Medicamen Biotech Ltd has improved by 2.99% and 13.35% in the same period respectively. Profit before tax (PBT) of Medicamen Biotech Ltd stood at Rs 2.57 crore in Q2 FY26, surging by 20.66% year-on-year, and tumbling by 49.21% quarter-on-quarter. EBITDA came in at Rs 3 crore, plunging by 16.18% YoY and slipping 6.22% sequentially. Total expenses saw a steep drop of 20.34% to Rs 45.36 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 22.61 crore, contracting by 13.34% YoY, while employee benefits expense was at Rs 9.31 crore, slipping by 0.96% YoY. For the TTM ended FY26, revenue from operations eased 9.35% to Rs 162.55 crore, while net profit witnessed a sharp fall of 30.87% to Rs 6.56 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 1889% to Rs 7.62 crore, and PBT collapsed by 24.46% to Rs 9.88 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 7.19 crore in FY26, as against Rs 0.37 crore in FY25. Medicamen Biotech Ltd nosedived by 29.78% in last one year, underperforming the benchmark BSE Sensex which has softened by 3.05% during the same period.

Medicamen Biotech Limited will hold a board meeting on Friday, August 14, 2026, to consider and approve the unaudited financial results (standalone and consolidated) for the quarter ended June 30, 2026, the draft annual report for the financial year 2025-26, and the draft cost audit report for the financial year 2025-26. The trading window for designated persons of the company has been closed since July 1, 2026, and will reopen 48 hours after the financial results are declared to stock exchanges.

Medicamen Biotech announced that the Board of Directors of the Company at its meeting held on 27 May 2026, inter alia, have recommended the final dividend of Rs 1 per equity Share (i.e. 10%) , subject to the approval of the shareholders.

Net profit of Medicamen Biotech rose 59.50% to Rs 3.86 crore in the quarter ended March 2026 as against Rs 2.42 crore during the previous quarter ended March 2025. Sales rose 104.83% to Rs 60.65 crore in the quarter ended March 2026 as against Rs 29.61 crore during the previous quarter ended March 2025. For the full year,net profit rose 35.58% to Rs 9.64 crore in the year ended March 2026 as against Rs 7.11 crore during the previous year ended March 2025. Sales rose 21.67% to Rs 197.77 crore in the year ended March 2026 as against Rs 162.55 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales60.6529.61 105 197.77162.55 22 OPM %8.97-5.44 -9.918.53 - PBDT6.792.97 129 19.2016.95 13 PBT5.062.49 103 11.989.88 21 NP3.862.42 60 9.647.11 36 Powered by Capital Market - Live

Medicamen Biotech will hold a meeting of the Board of Directors of the Company on 27 May 2026.

Net profit of Medicamen Biotech declined 36.89% to Rs 2.19 crore in the quarter ended December 2025 as against Rs 3.47 crore during the previous quarter ended December 2024. Sales rose 3.92% to Rs 46.91 crore in the quarter ended December 2025 as against Rs 45.14 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales46.9145.14 4 OPM %9.3414.86 - PBDT3.946.09 -35 PBT2.113.88 -46 NP2.193.47 -37 Powered by Capital Market - Live

Medicamen Biotech will hold a meeting of the Board of Directors of the Company on 13 February 2026.Powered by Capital Market - Live

Net profit of Medicamen Biotech rose 82.88% to Rs 2.67 crore in the quarter ended September 2025 as against Rs 1.46 crore during the previous quarter ended September 2024. Sales rose 5.43% to Rs 47.17 crore in the quarter ended September 2025 as against Rs 44.74 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales47.1744.74 5 OPM %10.9411.87 - PBDT4.544.56 0 PBT2.681.96 37 NP2.671.46 83 Powered by Capital Market - Live

Medicamen Biotech will hold a meeting of the Board of Directors of the Company on 14 November 2025.Powered by Capital Market - Live